COVID-19 THERAPY: COMPARISON EFFECTIVITY BETWEEN REMDESIVIR AND FAVIPIRAVIR

Nevan Go, P. A. Mellow, B. N. Dewi
{"title":"COVID-19 THERAPY: COMPARISON EFFECTIVITY BETWEEN REMDESIVIR AND FAVIPIRAVIR","authors":"Nevan Go, P. A. Mellow, B. N. Dewi","doi":"10.33508/jwmj.v4i4.4344","DOIUrl":null,"url":null,"abstract":"Introduction: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) is the virus that causes Coronavirus Disease 2019 (COVID-19), a disease of global concern(1). Remdesivir and favipiravir are antiviral drugs that are considered COVID19 therapy, as described in Indonesia's 3rd COVID-19 Management Guidelines. They have a similar mechanism, specifically by inhibiting RNA dependent RNA polymerase of the virus (3). Several studies have reported that patients who were treated with these antivirals had a shorter hospital stays (4–6). However, the comparison of efficacy between remdesivir and favipiravir is still unknown. Methods: An observational analytic study was done using a retrospective cohort design. Eighty-eight medical records of COVID-19 patients between January 2021 to August 2021 are collected by consecutive sampling techniques, and this research was carried out at Gotong Royong Hospital Surabaya. Results: Based on the statistical analysis test, there was no clinical improvement difference found, neither patients received remdesivir nor favipiravir based on their clinical manifestations, such as ventilation support and chest X-ray, measured by WHO ordinal scale (p=0,486 ; p>0,05 on the first week and p=0,942 ; p>0,05 on the second week). Conclusions: Improved clinical manifestations were seen in the second week of therapy, either in patients who received remdesivir or favipiravir, but there was no significant effectivity difference between those drugs.","PeriodicalId":192353,"journal":{"name":"Journal of Widya Medika Junior","volume":"8 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Widya Medika Junior","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33508/jwmj.v4i4.4344","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Introduction: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) is the virus that causes Coronavirus Disease 2019 (COVID-19), a disease of global concern(1). Remdesivir and favipiravir are antiviral drugs that are considered COVID19 therapy, as described in Indonesia's 3rd COVID-19 Management Guidelines. They have a similar mechanism, specifically by inhibiting RNA dependent RNA polymerase of the virus (3). Several studies have reported that patients who were treated with these antivirals had a shorter hospital stays (4–6). However, the comparison of efficacy between remdesivir and favipiravir is still unknown. Methods: An observational analytic study was done using a retrospective cohort design. Eighty-eight medical records of COVID-19 patients between January 2021 to August 2021 are collected by consecutive sampling techniques, and this research was carried out at Gotong Royong Hospital Surabaya. Results: Based on the statistical analysis test, there was no clinical improvement difference found, neither patients received remdesivir nor favipiravir based on their clinical manifestations, such as ventilation support and chest X-ray, measured by WHO ordinal scale (p=0,486 ; p>0,05 on the first week and p=0,942 ; p>0,05 on the second week). Conclusions: Improved clinical manifestations were seen in the second week of therapy, either in patients who received remdesivir or favipiravir, but there was no significant effectivity difference between those drugs.
新冠肺炎治疗:瑞德西韦与法匹拉韦的疗效比较
简介:严重急性呼吸综合征冠状病毒2 (SARS CoV-2)是引起全球关注的疾病2019冠状病毒病(COVID-19)的病毒(1)。如印度尼西亚第三版《2019冠状病毒病管理指南》所述,Remdesivir和favipiravir是被视为治疗COVID-19的抗病毒药物。它们具有相似的机制,特别是通过抑制病毒的RNA依赖性RNA聚合酶(3)。一些研究报道,接受这些抗病毒药物治疗的患者住院时间较短(4-6)。然而,瑞德西韦和法匹拉韦的疗效比较尚不清楚。方法:采用回顾性队列设计进行观察性分析研究。采用连续抽样技术收集了2021年1月至2021年8月期间88例COVID-19患者的医疗记录,本研究在泗水Gotong Royong医院进行。结果:经统计分析检验,两组患者均未发现临床改善差异,采用WHO分级量表对两组患者的通气支持、胸片等临床表现进行测量(p=0,486;第一周P > 0.05, P = 0.942;第2周P > 0.05)。结论:无论是瑞德西韦还是法匹拉韦,治疗第2周患者的临床表现均有所改善,但两种药物的疗效无显著差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信